Distinct pattern of reported adverse event with SGLT2 inhibitors in heart failure: A pharmacovigilance study using VigiBase data. (PubMed, Therapie) - Sep 19, 2026 - "SGLT2 inhibitor safety profiles differ across indications, shaped in part by patient characteristics. In heart failure, the reporting of unexpected serious events, such as ketoacidosis, and a higher proportion of fatal outcomes sharply reinforces the need for intensified safety surveillance."
Adverse events • Journal • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus • Urology
|
|
François Roubille; Jean-Luc Faillie; Nicolas Chapet; Omar Chebbo; Pascale Palassin
|